Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
The product will be manufactured at Lupin’s Somerset facility in the US
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Subscribe To Our Newsletter & Stay Updated
